Company Arcutis Biotherapeutics, Inc.

Equities

ARQT

US03969K1088

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Arcutis Biotherapeutics, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Real-time Estimate Cboe BZX Other stock markets 07:58:22 03/05/2024 pm IST			5-day change	1st Jan Change
8.49 ^USD	-1.28%		+1.18%	+165.33%

10/04	Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes	CI
18/03	Arcutis Biotherapeutics, Inc.(NasdaqGS:ARQT) added to S&P Biotechnology Select Industry Index	CI

Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Companyâs pipeline includes ARQ-255, ARQ-252, and ARQ-234. ARQ-255 is developed for alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo. ARQ-255 is developed for the treatment of alopecia areata.

Number of employees: 296

USD in Million	2022	Weight	2023	Weight	Delta
Dermatological Treatments 100.0 %	4	100.0 %	60	100.0 %	+1,517.09%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	4	100.0 %	60	100.0 %	+1,517.09%

Managers	Title	Age	Since
Todd Watanabe CEO	Chief Executive Officer	55	01/16/01
Rajvir Madan CTO	Chief Tech/Sci/R&D Officer	-	01/21/01
Jay Ramsinghani COO	Chief Operating Officer	-	27/20/27
Patrick Burnett CTO	Chief Tech/Sci/R&D Officer	52	01/20/01
Courtney Barton CMP	Compliance Officer	41	18/21/18
Howard Welgus BRD	Director/Board Member	72	01/16/01
Jessica Robison AUD	Comptroller/Controller/Auditor	-	01/19/01
Bruce Binkowitz PRN	Corporate Officer/Principal	-	23/21/23
Matthew Moore PRN	Corporate Officer/Principal	-	11/21/11
Charlotte Merritt LAW	General Counsel	61	01/17/01

Members of the board	Title	Age	Since
Patrick Heron CHM	Chairman	53	01/16/01
Bhaskar Chaudhuri FOU	Founder	69	01/16/01
Keith Leonard BRD	Director/Board Member	62	02/21/02
Halley Gilbert BRD	Director/Board Member	54	01/20/01
Howard Welgus BRD	Director/Board Member	72	01/16/01
Terrie Curran BRD	Director/Board Member	55	02/20/02
Todd Watanabe CEO	Chief Executive Officer	55	01/16/01
Sue-Jean Lin BRD	Director/Board Member	65	09/21/09
Neha Krishnamohan BRD	Director/Board Member	37	02/22/02

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	115,524,989	112,656,195 ( 97.52 %)	0	97.52 %

Name	Equities	%	Valuation
Jennison Associates LLC 10.81 %	12,176,315	10.81 %	121 M $
Jennison Associates LLC 10.77 %	12,128,533	10.77 %	120 M $
Frazier Management LLC 7.802 %	8,785,284	7.802 %	87 M $
Suvretta Capital Management LLC 7.525 %	8,473,101	7.525 %	84 M $
Rubric Capital Management LP 5.901 %	6,644,530	5.901 %	66 M $
POLAR CAPITAL HOLDINGS PLC 5.593 %	6,297,688	5.593 %	62 M $
Morgan Stanley Investment Management, Inc. 5.402 %	6,083,072	5.402 %	60 M $
BlackRock Advisors LLC 5.036 %	5,671,214	5.036 %	56 M $
Vanguard Fiduciary Trust Co. 4.348 %	4,896,513	4.348 %	49 M $
Point72 Asset Management LP 4.323 %	4,867,706	4.323 %	48 M $

Arcutis Biotherapeutics, Inc.

3027 Townsgate Road Suite 300

91361, Westlake Village

http://www.arcutis.com

address Arcutis Biotherapeutics, Inc.(ARQT)

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

8.6 USD

Average target price

18 USD

Spread / Average Target

+109.30%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ARCUTIS BIOTHERAPEUTICS, INC.	+165.33%	994M
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	103B
REGENERON PHARMACEUTICALS, INC.	+7.12%	101B
ARGENX SE	+4.25%	23.07B
BIONTECH SE	-13.07%	22.23B
GENMAB A/S	-4.83%	18.05B
WUXI APPTEC CO., LTD.	-39.98%	17.18B
BEIGENE, LTD.	-10.93%	16.94B
NEUROCRINE BIOSCIENCES, INC.	+6.90%	14.07B
SAREPTA THERAPEUTICS, INC.	+36.88%	12.35B

Bio Therapeutic Drugs